Affordable Weight Loss Drugs Enter the Indian Market

The landscape of obesity management in the country changed significantly this week. The introduction of generic semaglutide in India became a reality following the patent expiration of the innovator drug on March 20, 2026. Consequently, several domestic pharmaceutical giants have launched affordable versions of this popular medication. However, while the reduced cost provides a major benefit for accessibility, medical experts are advising a cautious approach for patients and prescribers alike.

Accessing Generic Semaglutide in India

Previously, the original versions of anti-obesity medications cost patients between Rs 14,000 and Rs 17,000 per month. These steep prices acted as a significant inhibitor for many of the 101 million adults living with obesity in India. Furthermore, the new generic entrants have drastically lowered the price barrier. Monthly treatment costs now range from approximately Rs 1,200 to Rs 5,000. Additionally, several major Indian companies are offering both oral and injectable formats. This shift allows a much larger segment of the population to consider medical intervention for metabolic and weight-related health issues.

Cold Chain Integrity and Bioequivalence Concerns

Despite the excitement surrounding lower prices, clinicians emphasize that quality must remain the priority. Specifically, Dr. Rajiv Kovil and other specialists highlight the necessity of maintaining a strict cold chain for peptide-based medications. Because peptides are highly sensitive to temperature fluctuations, improper storage can lead to denatured proteins and reduced efficacy. Therefore, doctors recommend a wait-and-watch approach to ensure that manufacturers and distributors can handle these complex logistics. Moreover, historical precedents suggest that some generic formulations may contain compounds that trigger mild allergic reactions. Patients should only use these medications under strict medical supervision to monitor for adverse effects during the initial months of therapy.

Frequently Asked Questions

Q1: What is the price difference between the original and generic versions?

The original brand-name medications cost between Rs 14,000 and Rs 17,000 per month. In contrast, the generic versions launched in India are priced between Rs 1,200 and Rs 5,000 monthly, depending on the manufacturer and dosage form.

Q2: Why is the cold chain so important for semaglutide?

Semaglutide is a peptide-based medication. These molecules are sensitive to heat and light. If the medication is not stored between 2°C and 8°C during transport and storage, the peptide can degrade, rendering the drug ineffective or potentially unsafe.

Q3: Are the generic versions as effective as the innovator drug?

While generic versions have undergone trials to prove bioequivalence, many experts suggest observing real-world patient outcomes for a month or two. This helps ensure that the specific formulation and delivery device meet the expected clinical standards.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Doctors advise cautious use of cheap generic anti-obesity medicines - ETHealthworld


2. Indian Pharma Companies Launch Semaglutide Generics Following Patent Expiry - LiveMint


3. Understanding Cold Chain Requirements for Peptide Medications - Ro Health Guide